ArticleBMC medical genetics2019
Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis.
Article in BMC medical genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 58 citations in OpenAlex.
- Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tumor mutational burden, gene expression patterns, and immune-cell deconvolution in testicular germ cell tumors.Translational andrology and urology · 2025Article
- Expanding the Knowledge of the Molecular Effects and Therapeutic Potential of Incomptine A for the Treatment of Non-Hodgkin Lymphoma: In Vivo and Bioinformatics Studies, Part III.Pharmaceuticals (Basel, Switzerland) · 2025Article
- RNA-Seq Uncovers Association of Endocrine-Disrupting Chemicals with Hub Genes and Transcription Factors in Aggressive Prostate Cancer.International journal of molecular sciences · 2025Article
- Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.Discover oncology · 2025Review
- Article
- Missense mutations of GPER1 in breast invasive carcinoma: Exploring gene expression, signal transduction and immune cell infiltration with insights from cellular pharmacology.Biomedical reports · 2025Article
- Article
- Downregulated MYL1 Emerges as a Promising Diagnostic Biomarker for Rheumatoid Arthritis.Journal of inflammation research · 2025Article
- Understanding the Molecular Mechanisms of Incomptine A in Treating Non-Hodgkin Lymphoma Associated with U-937 Cells: Bioinformatics Approaches, Part I.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Non-Susceptibility Gene Variants in Head and Neck Paragangliomas.International journal of molecular sciences · 2024Article
- Explainable Machine Learning Models Using Robust Cancer Biomarkers Identification from Paired Differential Gene Expression.International journal of molecular sciences · 2024Article
- MYH6 suppresses tumor progression by downregulating KIT expression in human prostate cancer.Scientific reports · 2024Article
- A systematic review of mechanisms of PTEN gene down-regulation mediated by miRNA in prostate cancer.Heliyon · 2024Article
- Inference of differential gene regulatory networks using boosted differential trees.Bioinformatics advances · 2024Article
- Data mining on identifying diagnosis and prognosis biomarkers in head and neck squamous carcinoma.Scientific reports · 2023Article
- Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome.Scientific reports · 2023Article
- Identification of the prognostic value of Th1/Th2 ratio and a novel prognostic signature in basal-like breast cancer.Hereditas · 2023Article
- Non-Association of Driver Alterations in PTEN with Differential Gene Expression and Gene Methylation in IDH1 Wildtype Glioblastomas.Brain sciences · 2023Article
- MYL5 as a Novel Prognostic Marker is Associated with Immune Infiltrating in Breast Cancer: A Preliminary Study.The breast journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (Pca) remains one of the leading adult malignancies. PTEN (Phosphatase and Tensin Homolog) mutant is the top common mutated genes in prostate cancer, which makes it a promising biomarker in future individualized treatment.
methodsWe obtained gene expression data of prostate cancer from TCGA (The Cancer Genome Atlas) database for analysis. We analyzed the DEGs (differentially expressed genes), and used online tools or software to analyze Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene set enrichment analysis (GSEA), Search Tool for the Retrieval of Interacting Genes/Proteins, and Molecular Complex Detection.
resultsLatest TCGA data showed PTEN mutation in about 22% patients. 1736 DEGs in total were identified. Results of gene functional enrichment analyses showed that muscle contraction, negative regulation of growth and multiple metabolic progression were significantly enriched. GNG13, ACTN2, POTEE, ACTA1, MYH6, MYH3, MYH7, MYL1, TNNC1 and TNNC2 were the top ten hub genes. Patients with PTEN mutation showed relatively decreased mRNA expression level of PTEN. Survival analysis indicated the risk of disease recurrence in patients with PTEN mutation.
conclusionsOur findings suggested that PTEN mutation in prostate cancer may induce changes in a variety of genes and pathways and affect disease progression, suggesting the significance of PTEN mutation in individualized treatment of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.